US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NovaBridge Biosciences

1.78

-0.0150-0.84%

Volume:95.42K

Turnover:168.78K

Market Cap:204.60M

PE:-2.57

High:1.82

Open:1.79

Low:1.76

Close:1.79

52wk High:6.79

52wk Low:1.46

Shares:115.27M

Float Shares:64.56M

Volume Ratio:0.35

T/O Rate:0.15%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.6900

EPS(LYR):-0.9225

ROE:-59.10%

ROA:-34.98%

PB:1.02

PE(LYR):-1.92

Loading ...

Overview Company News Filings

Novabridge Biosciences - to Initiate Registrational Phase 3 Combination Trial in Q4 2026 Using Orr as Primary Endpoint

THOMSON REUTERS

Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study

BUZZ-U.S. STOCKS ON THE MOVE-Biotechs, Agilent, Dow

Mid-Cap NovaBridge Biosciences Stock Jumps Fueled By Positive Study Data In Eye Disease

Benzinga_recent_news

BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Live Nation, NovaBridge

BUZZ-NovaBridge gains as eye disease drug shows promise in mid‑stage trial

Novabridge and Visara Announce Positive Results From Vis-101 Phase 2a Wet Amd Study

THOMSON REUTERS

Novabridge Biosciences: Topline Phase 2a Data Show Vis-101 Provides Rapid, Robust and Durable Treatment Responses in Wet Amd

THOMSON REUTERS

Novabridge Biosciences: Favorable Safety Profile and No Dose-Limiting Toxicity

THOMSON REUTERS

Novabridge Biosciences: Vis-101 Demonstrated Mean Bvca Improvements of >10 Etdrs Letters and Median Cst Reductions of 100-150 Mm

THOMSON REUTERS

NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/NBP/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","market":"US","secType":"STK","nameCN":"NovaBridge Biosciences","latestPrice":1.775,"timestamp":1788465110533,"preClose":1.79,"halted":0,"volume":95423,"delay":0,"changeRate":-0.008379888268156494,"floatShares":64563600,"shares":115266053,"eps":-0.69,"marketStatus":"Trading","change":-0.015,"latestTime":"09-03 15:53:05 EDT","open":1.79,"high":1.815,"low":1.755,"amount":168783.58215049998,"amplitude":0.03352,"askPrice":1.78,"askSize":5653,"bidPrice":1.77,"bidSize":2100,"shortable":3,"etf":0,"ttmEps":-0.69,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788465600000},"marketStatusCode":2,"adr":0,"adrRate":2.3,"listingDate":1579237200000,"exchange":"NASDAQ","adjPreClose":1.79,"preHourTrading":{"tag":"盘前","latestPrice":1.79,"preClose":1.79,"latestTime":"09:29 EDT","volume":648,"amount":1161.8299152,"timestamp":1788442199912,"change":0,"changeRate":0,"amplitude":0.01676},"postHourTrading":{"tag":"盘后","latestPrice":1.82,"preClose":1.79,"latestTime":"19:30 EDT","volume":300,"amount":540.09,"timestamp":1788391805629,"change":0.03,"changeRate":0.01676,"amplitude":0.01676},"volumeRatio":0.348297,"impliedVol":1.8929,"impliedVolPercentile":0.7736},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","floatShares":64563600,"roa":"-34.98%","roe":"-59.10%","lyrEps":-0.922468,"volumeRatio":0.348297,"shares":115266053,"dividePrice":0,"high":1.815,"amplitude":0.03352,"preClose":1.79,"low":1.755,"week52Low":1.46,"pbRate":"1.02","week52High":6.79,"institutionHeld":0,"latestPrice":1.775,"committee":-0.458274,"eps":-0.69,"divideRate":0,"volume":95423,"delay":0,"ttmEps":-0.69,"open":1.79,"prevYearClose":3.98,"prevWeekClose":1.84,"prevMonthClose":1.82,"prevQuarterClose":1.95,"fiveDayClose":1.89,"twentyDayClose":1.7,"sixtyDayClose":1.59},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NBP\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"NBP","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787212800000,"name":null,"time":"Pre-MKt","dateTimestamp":1787198400000,"actualEps":null},{"market":"US","date":"2026-04-07","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1775534400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-20","symbol":"NBP","fiscalQuarterEnding":"2025/06","expectedEps":-0.1,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"pre","actualEps":-0.07},{"market":"US","date":"2025-05-15","symbol":"NBP","fiscalQuarterEnding":"2025/03","expectedEps":-0.07,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.04},{"market":"US","date":"2025-04-03","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1743652800000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1759550400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NBP","date":"2026-09-02","current":-2.594203,"percent":1,"low":-20.276437,"twenty":-14.513199,"median":-10.607129,"eighty":-2.317159,"high":-1.707119,"avg":-8.423465,"sd":6.080639,"marketCap":200678643},"quantilePoints":[{"date":"2025-10-31","current":-13.114792,"twenty":-13.114792,"median":-13.114792,"eighty":-13.114792,"marketCap":524460541},{"date":"2025-11-07","current":-12.077138,"twenty":-13.547148,"median":-12.71126,"eighty":-12.278904,"marketCap":482964762},{"date":"2025-11-14","current":-12.019491,"twenty":-13.114792,"median":-12.278904,"eighty":-12.077138,"marketCap":480659441},{"date":"2025-11-21","current":-12.077138,"twenty":-13.085968,"median":-12.293316,"eighty":-12.077138,"marketCap":482964762},{"date":"2025-11-28","current":-11.068308,"twenty":-13.06291,"median":-12.192433,"eighty":-11.881137,"marketCap":442621643},{"date":"2025-12-05","current":-11.500664,"twenty":-12.688201,"median":-12.077138,"eighty":-11.212426,"marketCap":459911551},{"date":"2025-12-12","current":-11.298898,"twenty":-12.411494,"median":-12.033903,"eighty":-11.287368,"marketCap":451842927},{"date":"2025-12-19","current":-17.342266,"twenty":-12.688201,"median":-12.048315,"eighty":-11.460311,"marketCap":456552482},{"date":"2025-12-26","current":-20.276437,"twenty":-13.287734,"median":-12.077138,"eighty":-11.500664,"marketCap":533797473},{"date":"2026-01-02","current":-17.429853,"twenty":-17.342266,"median":-12.163609,"eighty":-11.512194,"marketCap":458858303},{"date":"2026-01-09","current":-16.597774,"twenty":-17.482405,"median":-12.235668,"eighty":-11.541017,"marketCap":436953007},{"date":"2026-01-16","current":-16.028458,"twenty":-17.394818,"median":-12.365376,"eighty":-11.569841,"marketCap":421965173},{"date":"2026-01-23","current":-17.03571,"twenty":-17.342266,"median":-13.057145,"eighty":-11.587135,"marketCap":448482110},{"date":"2026-01-30","current":-16.116045,"twenty":-17.3773,"median":-13.33097,"eighty":-11.615959,"marketCap":424270994},{"date":"2026-02-06","current":-14.583269,"twenty":-17.342266,"median":-14.495682,"eighty":-11.742783,"marketCap":383919133},{"date":"2026-02-13","current":-14.189126,"twenty":-17.307231,"median":-14.71465,"eighty":-11.823489,"marketCap":373542940},{"date":"2026-02-20","current":-14.539475,"twenty":-17.167091,"median":-14.517578,"eighty":-11.961843,"marketCap":382766222},{"date":"2026-02-27","current":-14.364301,"twenty":-17.03571,"median":-14.408094,"eighty":-12.019491,"marketCap":378154581},{"date":"2026-03-06","current":-15.94087,"twenty":-17.03571,"median":-14.386197,"eighty":-12.048315,"marketCap":419659352},{"date":"2026-03-13","current":-12.875318,"twenty":-16.991917,"median":-14.364301,"eighty":-12.077138,"marketCap":338955631},{"date":"2026-03-20","current":-11.780478,"twenty":-16.948123,"median":-14.316021,"eighty":-12.077138,"marketCap":310132873},{"date":"2026-03-27","current":-11.167368,"twenty":-16.597774,"median":-14.189126,"eighty":-11.788901,"marketCap":293992129},{"date":"2026-04-02","current":-10.773226,"twenty":-16.597774,"median":-14.101539,"eighty":-11.587135,"marketCap":283615936},{"date":"2026-04-10","current":-3.171352,"twenty":-16.387565,"median":-14.057746,"eighty":-11.527134,"marketCap":280157205},{"date":"2026-04-17","current":-3.495376,"twenty":-16.299978,"median":-13.61981,"eighty":-11.287368,"marketCap":308781505},{"date":"2026-04-24","current":-3.23355,"twenty":-16.221149,"median":-13.10038,"eighty":-11.118286,"marketCap":285651804},{"date":"2026-05-01","current":-3.23355,"twenty":-16.203632,"median":-12.875318,"eighty":-11.061844,"marketCap":285651804},{"date":"2026-05-08","current":-2.906268,"twenty":-16.133562,"median":-12.604261,"eighty":-10.634902,"marketCap":256739678},{"date":"2026-05-15","current":-2.513529,"twenty":-16.045975,"median":-12.365376,"eighty":-3.526795,"marketCap":222045127},{"date":"2026-05-22","current":-2.330251,"twenty":-15.993423,"median":-12.293316,"eighty":-3.374936,"marketCap":205854337},{"date":"2026-05-29","current":-2.448072,"twenty":-15.958388,"median":-12.192433,"eighty":-3.235384,"marketCap":216262702},{"date":"2026-06-05","current":-2.356433,"twenty":-15.651833,"median":-12.134786,"eighty":-3.190946,"marketCap":208167307},{"date":"2026-06-12","current":-1.92442,"twenty":-15.393451,"median":-12.062727,"eighty":-3.136675,"marketCap":170003300},{"date":"2026-06-18","current":-2.055333,"twenty":-15.340898,"median":-11.990667,"eighty":-3.100019,"marketCap":181568151},{"date":"2026-06-26","current":-2.094607,"twenty":-15.292725,"median":-11.780478,"eighty":-2.890558,"marketCap":185037606},{"date":"2026-07-02","current":-2.605168,"twenty":-15.231414,"median":-11.587135,"eighty":-2.686334,"marketCap":230140522},{"date":"2026-07-10","current":-2.434981,"twenty":-15.178862,"median":-11.559911,"eighty":-2.610404,"marketCap":215106217},{"date":"2026-07-17","current":-2.343342,"twenty":-15.091275,"median":-11.517717,"eighty":-2.516147,"marketCap":207010822},{"date":"2026-07-24","current":-2.317159,"twenty":-15.012446,"median":-11.399781,"eighty":-2.437599,"marketCap":204697852},{"date":"2026-07-31","current":-2.146972,"twenty":-14.977411,"median":-11.226206,"eighty":-2.42189,"marketCap":189663546},{"date":"2026-08-07","current":-2.22552,"twenty":-14.977411,"median":-11.123574,"eighty":-2.356433,"marketCap":196602456},{"date":"2026-08-14","current":-2.487346,"twenty":-14.84603,"median":-11.068308,"eighty":-2.356433,"marketCap":219732157},{"date":"2026-08-21","current":-1.87904,"twenty":-14.583269,"median":-11.035987,"eighty":-2.356433,"marketCap":220888642},{"date":"2026-08-28","current":-1.865003,"twenty":-14.539475,"median":-10.707535,"eighty":-2.330251,"marketCap":219238518},{"date":"2026-09-02","current":-1.707119,"twenty":-14.513199,"median":-10.607129,"eighty":-2.317159,"marketCap":200678643}],"updateTime":1788429732451},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NBP\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2619452136","title":"Novabridge Biosciences - to Initiate Registrational Phase 3 Combination Trial in Q4 2026 Using Orr as Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2619452136","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619452136?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:00","pubTimestamp":1773658803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA5VSGVC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619193779","title":"Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2619193779","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619193779?lang=en_us&edition=fundamental","pubTime":"2026-03-13 18:05","pubTimestamp":1773396300,"startTime":"0","endTime":"0","summary":"VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitor. Topline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet AMD. VIS-101 demonstrated mean BVCA improvements of >10 ETDRS letters and median CST reductions of 100-150 mm. Potentially best-in-class durability with a favorable safety profile and no dose-limiting toxicity. Phase 2b dose-determining study expected to begin in H2 2026; global Phase 3 program expected to begin in 2027. SHANGHAI, March 13, 2026 /PRNewswire/ --Everest Medicines  today announced that its licensing partner, NovaBridge Biopharma , together with its subsidiary Visara, Inc. , reported positive topline results from the Phase 2a study of VIS-101, a purpose-designed tetravalent, dual VEGF-A X ANG-2 inhibitor in development for retinal vascular diseases including wet age-related macular degeneration , diabetic macular edema , and retinal vein occlusion . Topl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/everest-medicines-licensing-partner-novabridge-and-visara-announce-positive-results-from-vis-101-phase-2a-wet-amd-study-302713298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0198837287.USD","LU1880398554.USD","LU1989764664.SGD","LU1064131342.USD","LU0274383776.USD","AMDU","BK4612","LU0823434740.USD","LU0889565833.HKD","BK4141","LU1303367103.USD","LU2250418816.HKD","LU2360106780.USD","NBP","LU2098885051.SGD","LU0390134368.USD","LU1316542783.SGD","BK4529","IE0009356076.USD","LU2089985449.USD","LU1852331112.SGD","LU1951198990.SGD","LU1242518931.SGD","LU0056508442.USD","LU1861559042.SGD","AMUU","BK4543","BK4139","BK4614","LU0823421416.USD","IE00BMPRXR70.SGD","DAMD","LU2458330243.SGD","BK4585","IE00BMPRXN33.USD","LU0719512351.SGD","01952","LU0109392836.USD","LU1923623000.USD","AMDY","LU0823421333.USD","LU0082616367.USD","AMDW","LU2458330169.SGD","LU0823434583.USD","LU1803068979.SGD","BK4532","LU1951200564.SGD","LU1880398471.USD","AMYY","BK4588","BK7095","LU0081259029.USD","LU2054465674.USD","BK4512","BK4573","BK4554","LU2355687059.USD","LU1988902786.USD","BK4575","LU0979878070.USD","AMDD","BK4566","LU0127658192.USD","AMDG","IE0004445239.USD","LU0642271901.SGD","LU1861558580.USD","BK4605","LU2264538146.SGD","LU1242518857.USD","AMDL","LU2931357623.SGD","IE00B5949003.HKD","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618620753","title":"BUZZ-U.S. STOCKS ON THE MOVE-Biotechs, Agilent, Dow","url":"https://stock-news.laohu8.com/highlight/detail?id=2618620753","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618620753?lang=en_us&edition=fundamental","pubTime":"2026-03-09 23:46","pubTimestamp":1773071217,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Biotechs, Agilent, DowWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:/","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL6N3ZX16R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX","PFE","NBP","XOMX","SATS","UAL","VRT","XOMO","ITT","AGH","DUK","IRON","NEM","SLB","NEMG","HIMZ","NWMX","CDE","JEF","LUV","JPMO","VRTL","XENE","FCEL","HL","HIMY","DTIL","AAL","DE","COHX","DAL","CAPR","HMYY","PLD","LYV","CAT","DOW","LITX","AALG","COP","XOMZ","RAPP","BAC","SATG","RLMD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618271622","title":"Mid-Cap NovaBridge Biosciences Stock Jumps Fueled By Positive Study Data In Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2618271622","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618271622?lang=en_us&edition=fundamental","pubTime":"2026-03-09 22:24","pubTimestamp":1773066240,"startTime":"0","endTime":"0","summary":"NovaBridge stock jumps after VIS-101 Phase 2a study shows strong vision improvement in wet age-related macular degeneration patients.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/09/Genetic-eye-disease-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/09/Genetic-eye-disease-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/03/51129866/mid-cap-novabridge-biosciences-stock-jumps-fueled-by-positive-study-data-in-eye-disease","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/03/51129866/mid-cap-novabridge-biosciences-stock-jumps-fueled-by-positive-study-data-in-eye-disease","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","BK4217","NBP","CST","SMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618621571","title":"BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Live Nation, NovaBridge","url":"https://stock-news.laohu8.com/highlight/detail?id=2618621571","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618621571?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:29","pubTimestamp":1773062964,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Live Nation, NovaBridgeWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL6N3ZX0ND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAT","COP","SATS","HIMZ","RLMD","DAL","DTIL","IE0034235303.USD","LU0997586606.USD","VRTL","ITT","LUV","NEM","XOMO","LU0203345920.USD","PFE","NEMG","RAPP","HL","IE00B19Z3581.USD","SLB","LYV","XOMX","HIMY","LU0868494708.USD","AALG","FCEL","PLD","BK4017","HIMS","HMYY","XENE","CDE","AAL","AGH","COHX","AU","NWMX","HIYY","LITX","UAL","XOMZ","BARC.UK","NBP","VRT","SATG"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618628309","title":"BUZZ-NovaBridge gains as eye disease drug shows promise in mid‑stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2618628309","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618628309?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:17","pubTimestamp":1773055058,"startTime":"0","endTime":"0","summary":"BUZZ-NovaBridge gains as eye disease drug shows promise in midstage trial** Shares of drug developer NovaBridge NBP.O rise 6.6% to $3.73 premarket** Co says its experimental drug, VIS-101, improved vision in people with wet age-related macular degeneration, a disease that damages the retina and causes vision loss in older adults** Adds patients gained more than 10 letters on a standard eye chart and had reduced retinal swelling in a mid-stage study ** Says nearly half of the 38 patients in the trial needed no additional treatment for six months after three doses** VIS101 well tolerated with no serious safety issues - co ** NBP plans larger dose-finding study in second-half of 2026 and global late-stage trial in 2027** Shares rose nearly four-fold in 2025  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL4N3ZX10Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618973640","title":"Novabridge and Visara Announce Positive Results From Vis-101 Phase 2a Wet Amd Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2618973640","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618973640?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054026,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX109:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618401666","title":"Novabridge Biosciences: Topline Phase 2a Data Show Vis-101 Provides Rapid, Robust and Durable Treatment Responses in Wet Amd","url":"https://stock-news.laohu8.com/highlight/detail?id=2618401666","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618401666?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054026,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX109:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618401606","title":"Novabridge Biosciences: Favorable Safety Profile and No Dose-Limiting Toxicity","url":"https://stock-news.laohu8.com/highlight/detail?id=2618401606","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618401606?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054026,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX109:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618132640","title":"Novabridge Biosciences: Vis-101 Demonstrated Mean Bvca Improvements of >10 Etdrs Letters and Median Cst Reductions of 100-150 Mm","url":"https://stock-news.laohu8.com/highlight/detail?id=2618132640","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618132640?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054026,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX109:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618244640","title":"NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2618244640","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618244640?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054000,"startTime":"0","endTime":"0","summary":"VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitorTopline Phase 2a data show VIS-101 provides rapid, robust and durable treatm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251682/0/en/NovaBridge-and-Visara-Announce-Positive-Results-from-VIS-101-Phase-2a-Wet-AMD-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2250418816.HKD","BK4573","LU1988902786.USD","BK4614","IE0004445239.USD","AMYY","BK4605","LU1303367103.USD","BK4588","BK4532","LU0127658192.USD","LU0979878070.USD","LU1989764664.SGD","IE00B5949003.HKD","LU0642271901.SGD","IE0009356076.USD","BK4575","LU1951200564.SGD","LU2458330243.SGD","LU2089985449.USD","LU2458330169.SGD","AMDU","BK4554","LU1852331112.SGD","AMDL","BK4585","LU2264538146.SGD","BK4534","LU0823434740.USD","LU1923623000.USD","AMDG","BK4141","LU0719512351.SGD","LU1861559042.SGD","LU2054465674.USD","NBP","LU0823421333.USD","LU1803068979.SGD","LU0056508442.USD","LU0274383776.USD","LU0889565833.HKD","BK4512","AMDW","AMUU","BK4543","LU0198837287.USD","LU1242518857.USD","DAMD","LU1880398554.USD","BK4566","BK4612","LU0082616367.USD","LU1242518931.SGD","LU2098885051.SGD","LU1861558580.USD","AMDY","LU1064131342.USD","LU1316542783.SGD","LU0823421416.USD","LU2931357623.SGD","LU0081259029.USD","LU0823434583.USD","LU2355687059.USD","AMDD","BK4529","LU1951198990.SGD","LU2360106780.USD","LU0109392836.USD","LU1880398471.USD","IE00BMPRXR70.SGD","LU0390134368.USD","IE00BMPRXN33.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":71,"code":"91000000","status":"200"}]}}